[Efficacy and safety of modified release zolpidem in patients with chronic insomnia].
to assess the efficacy and safety of zolpidem modified release (MR) on an "as per needed basis" in patients with chronic insomnia. one hundred and thirty five adult patients with chronic insomnia were recruited. Participants received zolpidem MR 12.5 mg during a 12 weeks period. Severity and improvement of insomnia were assessed at baseline and at the end of study using the clinical global impression scale; sleep quality was assessed by the application of the Pittsburgh Sleep Quality Index; drug consumption behavior was evaluated through tablet counting; in addition its security was assessed by the registry of the adverse effects. one hundred and fifteen patients completed the study; 83.7 % were considered improved or very improved, so that 66 % reached a normal or borderline condition. Twenty percent of subjects experienced adverse reactions; the most frequent were headache, excessive sleepiness, nausea and dizziness. these data support the efficacy, safety and acceptance of zolpidem MR administered on an "as per needed" regimen for the treatment of chronic insomnia.